Adverum Biotechnologies Stock Performance
| ADVM Stock | USD 5.10 0.50 8.93% |
Adverum Biotechnologies has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.12, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Adverum Biotechnologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Adverum Biotechnologies is expected to be smaller as well. Adverum Biotechnologies right now shows a risk of 4.89%. Please confirm Adverum Biotechnologies value at risk, as well as the relationship between the skewness and day median price , to decide if Adverum Biotechnologies will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Adverum Biotechnologies are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Adverum Biotechnologies may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Actual Historical Performance (%)
One Day Return 5.88 | Five Day Return 2.86 | Year To Date Return 12.5 | Ten Year Return (98.68) | All Time Return (98.07) |
Last Split Factor 1:10 | Last Split Date 2024-03-21 |
1 | Adverum Biotechnologies, Inc. Sees Large Increase in Short Interest - MarketBeat | 12/31/2024 |
2 | Adverum Biotechnologies to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference | 02/05/2025 |
3 | Acquisition by Svoronos Dawn of 40000 shares of Adverum Biotechnologies subject to Rule 16b-3 | 02/14/2025 |
4 | 3 US Penny Stocks With Market Caps Below 400M - Simply Wall St | 02/18/2025 |
5 | How Is Adverum Biotechnologies Positioned in the Gene Therapy Sector | 02/25/2025 |
6 | Acquisition by Leonard Braden Michael of 164886 shares of Adverum Biotechnologies at 4.0087 subject to Rule 16b-3 | 02/26/2025 |
7 | Acquisition by Leonard Braden Michael of 86802 shares of Adverum Biotechnologies at 4.4595 subject to Rule 16b-3 | 02/27/2025 |
8 | Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/28/2025 |
9 | Oppenheimer maintains Outperform on Adverum stock, 32 target - Investing.com | 03/04/2025 |
10 | Acquisition by Leonard Braden Michael of 18000 shares of Adverum Biotechnologies at 4.6 subject to Rule 16b-3 | 03/18/2025 |
11 | Acquisition by Leonard Braden Michael of 25000 shares of Adverum Biotechnologies at 4.9356 subject to Rule 16b-3 | 03/19/2025 |
12 | Acquisition by Leonard Braden Michael of 30600 shares of Adverum Biotechnologies at 5.6133 subject to Rule 16b-3 | 03/20/2025 |
13 | Acquisition by Laurent Fischer of 200000 shares of Adverum Biotechnologies at 7.15 subject to Rule 16b-3 | 03/21/2025 |
| Begin Period Cash Flow | 70.9 M |
Adverum |
Adverum Biotechnologies Relative Risk vs. Return Landscape
If you would invest 502.00 in Adverum Biotechnologies on December 25, 2024 and sell it today you would earn a total of 8.00 from holding Adverum Biotechnologies or generate 1.59% return on investment over 90 days. Adverum Biotechnologies is currently generating 0.1451% in daily expected returns and assumes 4.8894% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Adverum, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Adverum Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Adverum Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Adverum Biotechnologies, and traders can use it to determine the average amount a Adverum Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0297
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | ADVM | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.89 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.15 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Adverum Biotechnologies is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Adverum Biotechnologies by adding it to a well-diversified portfolio.
Adverum Biotechnologies Fundamentals Growth
Adverum Stock prices reflect investors' perceptions of the future prospects and financial health of Adverum Biotechnologies, and Adverum Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Adverum Stock performance.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (29.22) % | ||||
| Current Valuation | 26.43 M | ||||
| Shares Outstanding | 20.8 M | ||||
| Price To Earning | (2.10) X | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 106.09 X | ||||
| Revenue | 3.6 M | ||||
| Gross Profit | (67.22 M) | ||||
| EBITDA | (118.35 M) | ||||
| Net Income | (117.17 M) | ||||
| Cash And Equivalents | 235.84 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 75.04 M | ||||
| Debt To Equity | 0.43 % | ||||
| Current Ratio | 8.03 X | ||||
| Book Value Per Share | 6.93 X | ||||
| Cash Flow From Operations | (90.9 M) | ||||
| Earnings Per Share | (5.95) X | ||||
| Market Capitalization | 106.09 M | ||||
| Total Asset | 173.01 M | ||||
| Retained Earnings | (919.78 M) | ||||
| Working Capital | 77.86 M | ||||
| Current Asset | 260.99 M | ||||
| Current Liabilities | 6.57 M | ||||
About Adverum Biotechnologies Performance
By examining Adverum Biotechnologies' fundamental ratios, stakeholders can obtain critical insights into Adverum Biotechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Adverum Biotechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.96) | (0.91) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (1.61) | (1.53) |
Things to note about Adverum Biotechnologies performance evaluation
Checking the ongoing alerts about Adverum Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Adverum Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Adverum Biotechnologies had very high historical volatility over the last 90 days | |
| Adverum Biotechnologies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.6 M. Net Loss for the year was (117.17 M) with loss before overhead, payroll, taxes, and interest of (67.22 M). | |
| Adverum Biotechnologies currently holds about 235.84 M in cash with (90.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37. | |
| Adverum Biotechnologies has a frail financial position based on the latest SEC disclosures | |
| Roughly 75.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Acquisition by Leonard Braden Michael of 25000 shares of Adverum Biotechnologies at 4.9356 subject to Rule 16b-3 |
- Analyzing Adverum Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Adverum Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Adverum Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Adverum Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Adverum Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Adverum Biotechnologies' stock. These opinions can provide insight into Adverum Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.95) | Revenue Per Share | Quarterly Revenue Growth (0.70) | Return On Assets | Return On Equity |
The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.